Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Investor Presentation (October 2020)
28 slides from Pyc Therapeutics's investor presentation, Oct 20, 2020
Slide 1: Business & Equity Raising Overview
Life-changing science Business & Equity Raising Overview October 2020
Slide 2: Important notice and disclaimer
Important notice and disclaimer page 1 of 2 The following notice and disclaimer applies to this investor presentation (Presentation). You should carefully read this notice and disclaimer before reading or making any other use of this Presentation or any information contained within it. This Presenta
Slide 3: Important notice and disclaimer
Important notice and disclaimer page 2 of 2 Effect of rounding A number of figures, amounts, percentages, estimates, calculations of value and fractions in this Presentation are subject to the effect of rounding. The actual calculation of these figures may differ from the figures set out in this Pre
Slide 4: Investment highlights
Investment highlights “PYG: ZZ
Slide 5: Key investment highlights
Key investment highlights PYC is an RNA therapeutics company specialising in diseases of the eye ▪ RNA therapeutics have come of age But their ongoing success is impeded by inefficient or toxic delivery inside cells ▪ PYC’s cell-penetrating peptide (CPP) delivery platform solves this ‘delivery’ prob
Slide 6: PYC has multiple assets heading towards multi-billion dollar target markets
PYC has multiple assets heading towards multi-billion dollar target markets – each with a clear competitive advantage 1 PYC is a drug development company with multiple assets – each heading towards a multi-billion dollar market Estimated market size Organ Program Target Discovery Pre-clinical IND-en
Slide 7: Equity Raising to fund multiple programs through clinical read-outs
Equity Raising to fund multiple programs through clinical read-outs PYC’s potential development pipeline in 2025 with successful completion of $55m raising Milestones (anticipated timing) Organ Program Discovery Pre-clinical IND-enabling Clinical Marketed Ocular VP-001 Retinitis Pigmentosa type 11 •
Slide 8: A$55m Equity Raising Overview
A$55m Equity Raising Overview 8
Slide 9: A$55m Equity Raising Overview
A$55m Equity Raising Overview Rationale and PYC is accelerating multiple drug programs towards clinical development on the back of a series of Summary successful milestones in pre-clinical development. The Company is seeking to raise gross proceeds of up to ~A$55m to progress multiple drug programs
Slide 10: Indicative timetable
Indicative timetable Key event Indicative Date Announcement of the Entitlement Offer 20 October 2020 Institutional Entitlement Offer Opens 20 October 2020 Placement and Institutional Entitlement Offer Closes 21 October 2020 Shares recommence trading on ASX on an “ex-entitlement” basis 22 October 202
Slide 11: Use of funds
Use of funds Company objectives Intended use of funds ▪ Continued development of VP-001 for Retinitis Pigmentosa Type 11, Clinical development of VP-001 through to market $10M reaching clinical development early in 2022 including Phase 1/2 and Phase 2/3 trials ▪ Proof of concept and IND-enabling stu
Slide 12: Proforma Balance Sheet
Proforma Balance Sheet PYC balance sheet, A$ FY2020 Pro forma1 ▪ Entitlement Offer net proceeds of up to $52m after costs of approximately $3m Cash and cash equivalents2 25,428,095 77,428,095 Other current assets 133,024 133,024 ▪ Pro forma cash available on completion Total current assets 25,561,11
Slide 13: Peer comparisons in RNA therapeutics
Peer comparisons in RNA therapeutics 13
Slide 14: PYC trades at a substantial discount to its US peers
PYC trades at a substantial discount to its US peers Market Cap. USD M1 Cash, USD M2 Stage IND date Platform Lead target 380 4183 18 563 Pre-clinical 1H 22 RNA delivery Rare Ocular 1,070 345 Pre-clinical 2H 21 RNA delivery Rare Muscle 790 375 Pre-clinical 1H 22 RNA delivery Rare Muscle 1,310 215 Pha
Slide 15: PYC has charted a path to 'closing the gap'
PYC has charted a path to ‘closing the gap’ Value drivers Focus to ‘close the gap’ in 2021 1 Progress VP-001 to clinic ▪ Demonstrate safety in large animal toxicity studies 2 Scale PYC’s CPP-PMO ▪ Progress VEGF and OPA1 programs through IND- technology enabling efficacy read-outs ▪ Add initial CNS p
Slide 16: Forward view of milestones
Forward view of milestones 16
Slide 17: 2021 will see PYC deliver a significant milestone across each pipeline program
2021 will see PYC deliver a significant milestone across each of its three pipeline programs (and beyond) Organ Program Target Milestone and anticipated timing Importance 1H21 2H21 Eye VP-001 PRPF31 Large animal toxicity studies Large animal pharmacokinetic • Final two major milestones before clinic
Slide 18: Corporate overview
Corporate overview 18
Slide 19: PYC Corporate Snapshot (ASX: PYC)
PYC Corporate Snapshot (ASX: PYC) Financial Information (15 October 2020, AUD) Share Price Performance (12 months) ASX website Share price $0.185 Number of shares 2,930M Market Capitalisation $542M Cash (30-Jun-20) $25M Debt (30-Jun-20) Nil Enterprise Value $517M Board of Director Alan Tribe – Chair
Slide 20: Leadership team
Leadership team Executive management Dr Rohan Hockings Professor Sue Fletcher Kaggen Ausma MBBS (Hons), JD GDLP PhD, BSc LLB, Becons (Hons) Chief Executive Officer Chief Scientific Officer Chief Business Officer Experience across both clinical Leading global expert and pioneer Previous roles in McKi
Slide 21: Appendix A: General risks
Appendix A: General risks COVID-19 and global health risks Global health risks or the potential for these events could have a negative impact on PYC. Since early 2020 the coronavirus pandemic, now known as COVID19, has spread rapidly to many countries globally. The impact of COVID-19 has led to the
Slide 22: Appendix A: General risks
Appendix A: General risks Operational success is uncertain Clinical trials are complex projects and sometimes fail to provide the anticipated data. For example, the inability to recruit sufficient numbers of patients, or the practical challenges associated with capturing the necessary data, can caus
Slide 23: Appendix A: General risks
Appendix A: General risks PYC is dependent on protection of its PYC’s lead drug program is protected by an extensive suite of granted and pending international patents, and also depends on proprietary know-how, trade intellectual property secrets, and confidential information. If any of these be com
Slide 24: Appendix A: General risks
Appendix A: General risks Dependence on commercial partners PYC utilises third parties, including suppliers and third-party service providers for product development, manufacture and commercialisation of products, and certain financial transactional processes. For example, the operation of clinical
Slide 25: Appendix A: Risks specific to an investment in the Company
Appendix A: Risks specific to an investment in the Company Demand may exceed available shares Under the Offer eligible existing shareholders will have the ability to apply for new shares pro rata, and any such applications will be met. PYC’s ability to meet applications by new shareholders and by ex
Slide 26: Appendix A: Risks specific to an investment in the Company
Appendix A: Risks specific to an investment in the Company Investment in equity capital markets There are risks associated with investment in any company listed on the ASX, which include both the financial and operational performance of PYC and and COVID-19 external factors outside PYC’s control, su
Slide 27: Appendix B: International Offer Restrictions
Appendix B: International Offer Restrictions INTERNATIONAL OFFER RESTRICTIONS Overseas Shareholders This presentation does not constitute an offer of New Shares in any jurisdiction in which it would be unlawful. In particular, this presentation may not be distributed to any person, and the New Share
Slide 28: Disclaimer
Disclaimer The purpose of this presentation is to provide an update of the business of PYC Therapeutics Limited trading as PYC Therapeutics Limited (ASX:PYC) (‘PYC’). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or cl
PYC Therapeutics — Investor Presentation (October 2020) on 6ix